clinical trial · NCT02644369
Study of the Effects of Pembrolizumab in Patients With Advanced Solid Tumors
University Health Network, Toronto·phase2·active not recruiting·n = 100
Squamous Cell Cancer of Head and NeckTriple Negative Breast CancerEpithelial Ovarian CancerMalignant MelanomaAdvanced Solid TumorsPembrolizumab
brief summary
This is a phase 2 study whose main purpose is to evaluate gene changes and immune biomarkers in patients with solid tumors during treatment with pembrolizumab and in relation to response to treatment. Pembrolizumab is a monoclonal antibody that is designed to block a protein called programmed cell death 1 ligand 1 (PD-L1) which will allow the body's immune system to kill the cancer cells.
started
Mar 21, 2016
primary completion
Dec 1, 2026
completion
Dec 1, 2026
last updated
Oct 1, 2026
detailed description
This study will involve treatment with pembrolizumab, tests and procedures done for safety, and the collection of archival tumor tissue, fresh tumor biopsies, and blood samples for biomarker research (including genetic testing).
official title
Investigator-initiated Phase II Study of Pembrolizumab Immunological Response Evaluation
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol